dc.contributor.author | Rossello, Xavier | |
dc.contributor.author | Rodriguez-Sinovas, Antonio | |
dc.contributor.author | Vilahur, Gemma | |
dc.contributor.author | Crisóstomo, Verónica | |
dc.contributor.author | Jorge, Inmaculada | |
dc.contributor.author | Zaragoza Sánchez, Carlos | |
dc.contributor.author | Zamorano, José L. | |
dc.contributor.author | Bermejo, Javier | |
dc.contributor.author | Ordóñez, Antonio | |
dc.contributor.author | Boscá, Lisardo | |
dc.contributor.author | Vázquez, Jesús | |
dc.contributor.author | Badimón, Lina | |
dc.contributor.author | Sánchez-Margallo, Francisco M. | |
dc.contributor.author | Fernández-Avilés, Francisco | |
dc.contributor.author | Garcia-Dorado, David | |
dc.contributor.author | Ibáñez, Borja | |
dc.date.accessioned | 2020-01-16T12:28:13Z | |
dc.date.available | 2020-01-16T12:28:13Z | |
dc.date.issued | 2019 | |
dc.identifier.issn | 2045-2322 | spa |
dc.identifier.uri | http://hdl.handle.net/10641/1807 | |
dc.description.abstract | Despite many cardioprotective interventions have shown to protect the heart against ischemia/
reperfusion injury in the experimental setting, only few of them have succeeded in translating their
findings into positive proof-of-concept clinical trials. Controversial and inconsistent experimental
and clinical evidence supports the urgency of a disruptive paradigm shift for testing cardioprotective
therapies. There is a need to evaluate experimental reproducibility before stepping into the clinical
arena. The CIBERCV (acronym for Spanish network-center for cardiovascular biomedical research) has
set up the “Cardioprotection Large Animal Platform” (CIBER-CLAP) to perform experimental studies
testing the efficacy and reproducibility of promising cardioprotective interventions based on a prespecified
design and protocols, randomization, blinding assessment and other robust methodological
features. Our first randomized, control-group, open-label blinded endpoint experimental trial assessing
local ischemic preconditioning (IPC) in a pig model of acute myocardial infarction (n = 87) will be carried
out in three separate sets of experiments performed in parallel by three laboratories. Each set aims
to assess: (A) CMR-based outcomes; (B) histopathological-based outcomes; and (C) protein-based
outcomes. Three core labs will assess outcomes in a blinded fashion (CMR imaging, histopathology and
proteomics) and 2 methodological core labs will conduct the randomization and statistical analysis. | spa |
dc.language.iso | eng | spa |
dc.publisher | Scientific Reports | spa |
dc.rights | Atribución-NoComercial-SinDerivadas 3.0 España | * |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/3.0/es/ | * |
dc.title | CIBER-CLAP (CIBERCV Cardioprotection Large Animal Platform): A multicenter preclinical network for testing reproducibility in cardiovascular interventions. | spa |
dc.type | journal article | spa |
dc.type.hasVersion | AM | spa |
dc.rights.accessRights | open access | spa |
dc.description.extent | 1525 KB | spa |
dc.identifier.doi | 10.1038/s41598-019-56613-6 | spa |
dc.relation.publisherversion | https://www.nature.com/articles/s41598-019-56613-6 | spa |